lung cancer
Conditions
Interventions
experience group:Intrapleural infusion of bevacizumab
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) The subjects voluntarily participated in the study and signed the informed consent form (2) The malignant pleural effusion of primary lung cancer was diagnosed by biopsy in the Department of pathology of our hospital; (3) There was at least >5cm pleural effusion at baseline; (4) There is no gender limit, and the age is 18-75 years old; (5) The score of ECoG is 0-2; (6) Have sufficient bone marrow hematopoietic and organ functions; (7) The subjects can communicate well with the researchers, and are willing and willing to comply with the requirements of this study; (8) The toxicity of previous anti-tumor treatment returned to = grade 1
Exclusion criteria
Exclusion criteria: (1) Combined with non primary lung tumor (2) Patients with other cardiovascular and cerebrovascular diseases, autoimmune defects, organ dysfunction or mental disorders (3) Patients with an estimated survival time = 1 month (4) Patients receiving bevacizumab within 3 months before admission (5) Pregnant or lactating patients (6) There is currently uncontrolled serious infection; (7) Uncontrolled central nervous system metastasis with intracranial hypertension; (8) Bleeding tendency, especially obvious gastrointestinal bleeding in recent 4 weeks, or being treated with thrombolysis or anticoagulation; (9) Severe chronic obstructive pulmonary disease and / or respiratory failure, severe intestinal adhesion; (10) Subjects participate in other experiments at the same time (11) Known allergy to the test drug and its excipients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS;Overall survival, OS; | — |
Countries
China
Contacts
Public ContactYongshun Chen
Renmin Hospital of Wuhan University
Outcome results
None listed